Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J68D | ISIN: CNE100001M79 | Ticker-Symbol: 08HH
Tradegate
27.06.25 | 18:53
1,821 Euro
+3,17 % +0,056
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD Chart 1 Jahr
5-Tage-Chart
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,7251,82119:27
1,7251,82119:28

Aktuelle News zur SHANGHAI FOSUN PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SHANGHAI FOSUN PHARMACEUTICAL Aktie jetzt für 0€ handeln
DoFosun Pharma prices $34.25M Nature's Sunshine share sale6
DoFOSUN PHARMA (02196): NEXT DAY DISCLOSURE RETURN - SHARE BUYBACK6
DiFOSUN PHARMA (02196): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 20244
DiFOSUN PHARMA (02196): POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE AGM, THE 2025 FIRST A SHAREHOLDERS' CLASS MEETING AND THE 2025 FIRST H SHAREHOLDERS' ...2
DiFOSUN PHARMA (02196): TERMS OF REFERENCE AND IMPLEMENTATION RULES OF THE STRATEGIC COMMITTEE UNDER THE BOARD OF DIRECTORS-
DiFOSUN PHARMA (02196): TERMS OF REFERENCE AND IMPLEMENTATION RULES OF THE AUDIT COMMITTEE UNDER THE BOARD OF DIRECTORS-
DiFOSUN PHARMA (02196): TERMS OF REFERENCE AND IMPLEMENTATION RULES OF THE NOMINATION COMMITTEE UNDER THE BOARD OF DIRECTORS-
DiFOSUN PHARMA (02196): TERMS OF REFERENCE AND IMPLEMENTATION RULES OF THE REMUNERATION AND APPRAISAL COMMITTEE UNDER THE BOARD OF DIRECTORS-
DiFOSUN PHARMA (02196): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTION2
DiFOSUN PHARMA (02196): (1) RE-APPOINTMENT OF CHAIRMAN, CO-CHAIRMAN AND VICE CHAIRMAN, (2) APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND PRESIDENT, CO-PRESIDENTS, ...1
DiFOSUN PHARMA (02196): ARTICLES OF ASSOCIATION3
17.06.Teva to collaborate with Fosun Pharma for TEV-562789
16.06.Teva, Fosun Pharma Partner to Develop Immuno-Oncology Therapy14
16.06.Teva, Shanghai Fosun Partner To Develop TEV-56278 390PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Monday said that they have partnered to develop TEV-56278.Teva's TEV-56278...
► Artikel lesen
16.06.Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology133Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva...
► Artikel lesen
16.06.Teva Pharmaceutical Industries Ltd: Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology381Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE therapy in Phase 1 for the treatment of various forms of cancer, including melanomaFosun Pharma-Teva collaboration agreement established with...
► Artikel lesen
13.06.FOSUN PHARMA (02196): NEXT DAY DISCLOSURE RETURN - SHARE BUYBACK3
06.06.FOSUN PHARMA (02196): ANNOUNCEMENT REGARDING ELECTION OF EMPLOYEE DIRECTOR4
06.06.FOSUN PHARMA (02196): ARTICLES OF ASSOCIATION3
06.06.FOSUN PHARMA (02196): ANNOUNCEMENT - CHANGES TO THE REGISTERED CAPITAL AND ARTICLES OF ASSOCIATION1
Weiter >>
88 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1